Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1Dermatologic 1CNS 1

Conditions

Neuroendocrine Tumors 7Neoplasms 6Colorectal Neoplasms 5Carcinoma, Hepatocellular 5Carcinoid Tumor 5Stomach Neoplasms 4Esophageal Neoplasms 4Acromegaly 4Weight Loss 3Rectal Neoplasms 3Pancreatic Neoplasms 3Diarrhea 3Carcinoma 3Breast Neoplasms 3Vipoma 2Thymoma 2Somatostatinoma 2Pituitary Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Malnutrition 2Intestinal Obstruction 2Insulinoma 2Glucagonoma 2Colonic Neoplasms 2Carcinoma, Islet Cell 2Adenoma, Islet Cell 2Zollinger-Ellison Syndrome 1Waldenstrom Macroglobulinemia 1Vulvar Neoplasms 1

Interventions

vandetanib 9Everolimus 4Sorafenib 3sargramostim 2cabozantinib 2Trastuzumab 2Sunitinib 2Gefitinib 2Doxorubicin 2yeast-CEA vaccine 1vatalanib 1tumor necrosis factor-alpha, CNGRC fusion protein, human 1tipifarnib 1temsirolimus 1tanespimycin 1sacubitril and valsartan sodium hydrate drug combination 1pralsetinib 1pembrolizumab 1pazopanib 1pasireotide 1nintedanib 1motesanib diphosphate 1mercaptoundecahydrododecaborate 1lenvatinib 1fluorodopa F 18 1cixutumumab 1anlotinib 1aldesleukin 1Vorinostat 1Vinorelbine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoma, Medullary × Octreotide × Clear all
NCT01204476 2016-07-15

Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma

National Cancer Institute (NCI)

Phase 1 Completed
27 enrolled
CNSDermatologicEndocrine

Glucagonoma, Insulinoma, Paraganglioma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡